Misha Komarov, founder of [alloc] init, is developing a Zcash-style private pool for Bitcoin that operates without a soft fork or code changes. This system uses witness encryption to lock Bitcoin keys, allowing users to make private transactions by depositing bitcoin into a shielded pool and using encrypted notes to spend or withdraw. While this approach increases transaction fees by about four times due to larger encrypted notes, it enhances privacy as more users join. The technology remains experimental, with ongoing efforts to reduce encrypted file sizes and improve security through audits. Komarov encourages Bitcoin users to provide feedback now as the design phase is time-sensitive, though no launch date has been set.
Bitcoin privacy enhancement developments provide context for cryptocurrency market activity as of Sep 25, 2026 01:32 WIB. For readers following major cryptocurrencies on Pluang, 43 out of 50 rose today while 6 fell. Notable price changes include EOS at Rp12.649 with an 8.13% increase and a typical hold time of 87 days, LINK at Rp235.571 up 7.95% with a 60% sell order activity, and FIL at Rp17.897 rising 7.63% with a 62% sell order activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
